-+ 0.00%
-+ 0.00%
-+ 0.00%

SciBase Q1 net loss widens to SEK 24.49 million; net sales rise 61% to SEK 14.28 million

PUBT·05/07/2026 06:02:06
Listen to the news
SciBase Q1 net loss widens to SEK 24.49 million; net sales rise 61% to SEK 14.28 million
  • SciBase posted Q1 net sales of SEK 14.28 million, up 61%, while net loss widened to SEK 24.49 million.
  • Loss per share narrowed to SEK 0.03 from SEK 0.07, while gross margin fell 21.3 percentage points to 49.2%.
  • Operating cash flow remained negative at SEK 26.57 million; cash and cash equivalents rose to SEK 71.26 million.
  • Electrode sales volume climbed 70% to 30,460 units, while US skin cancer market sales rose 79%.
  • Quarter included continued deliveries to Castle Biosciences for clinical studies, FDA clearance for extended US labeling, and inclusion of Nevisense (EIS) in US NCCN Melanoma Guidelines.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20260506:BIT:9453:0) on May 07, 2026, and is solely responsible for the information contained therein.